182 related articles for article (PubMed ID: 7844541)
21. The avirulent A7 Strain of Semliki Forest virus has reduced cytopathogenicity for neuroblastoma cells compared to the virulent L10 strain.
Atkins GJ
J Gen Virol; 1983 Jun; 64 (Pt 6)():1401-4. PubMed ID: 6854273
[TBL] [Abstract][Full Text] [Related]
22. The genomic sequence of defective interfering Semliki Forest virus (SFV) determines its ability to be replicated in mouse brain and to protect against a lethal SFV infection in vivo.
Thomson M; White CL; Dimmock NJ
Virology; 1998 Feb; 241(2):215-23. PubMed ID: 9499796
[TBL] [Abstract][Full Text] [Related]
23. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector.
Smyth JW; Fleeton MN; Sheahan BJ; Atkins GJ
Gene Ther; 2005 Jan; 12(2):147-59. PubMed ID: 15372069
[TBL] [Abstract][Full Text] [Related]
24. A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus.
Vähä-Koskela MJ; Tuittila MT; Nygårdas PT; Nyman JK; Ehrengruber MU; Renggli M; Hinkkanen AE
J Neurovirol; 2003 Feb; 9(1):1-15. PubMed ID: 12587064
[TBL] [Abstract][Full Text] [Related]
25. Functional significance of the nuclear-targeting and NTP-binding motifs of Semliki Forest virus nonstructural protein nsP2.
Rikkonen M
Virology; 1996 Apr; 218(2):352-61. PubMed ID: 8610462
[TBL] [Abstract][Full Text] [Related]
26. Aurothiolates enhance the replication of Semliki Forest virus in the CNS and the exocrine pancreas.
Scallan MF; Fazakerley JK
J Neurovirol; 1999 Aug; 5(4):392-400. PubMed ID: 10463861
[TBL] [Abstract][Full Text] [Related]
27. Cell death mechanisms in the olfactory bulb of rats infected intranasally with Semliki forest virus.
Sammin DJ; Butler D; Atkins GJ; Sheahan BJ
Neuropathol Appl Neurobiol; 1999 Jun; 25(3):236-43. PubMed ID: 10417665
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.
Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A
J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187
[TBL] [Abstract][Full Text] [Related]
29. Death mechanisms in cultured cells infected by Semliki Forest virus.
Glasgow GM; McGee MM; Sheahan BJ; Atkins GJ
J Gen Virol; 1997 Jul; 78 ( Pt 7)():1559-63. PubMed ID: 9225029
[TBL] [Abstract][Full Text] [Related]
30. Investigations of reasons for the avirulence of the A7 strain of Semliki Forest virus in adult mice.
Woodward CG; Marshall ID; Smith H
Br J Exp Pathol; 1977 Dec; 58(6):616-24. PubMed ID: 607983
[TBL] [Abstract][Full Text] [Related]
31. Virulence of a mouse-adapted Semliki Forest virus strain is associated with reduced susceptibility to interferon.
Deuber SA; Pavlovic J
J Gen Virol; 2007 Jul; 88(Pt 7):1952-1959. PubMed ID: 17554028
[TBL] [Abstract][Full Text] [Related]
32. Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis.
Amor S; Scallan MF; Morris MM; Dyson H; Fazakerley JK
J Gen Virol; 1996 Feb; 77 ( Pt 2 )():281-91. PubMed ID: 8627232
[TBL] [Abstract][Full Text] [Related]
33. Protection of mice infected with a lethal dose of Semliki Forest virus by defective interfering virus: modulation of virus multiplication.
Barrett AD; Guest AR; Mackenzie A; Dimmock NJ
J Gen Virol; 1984 Nov; 65 ( Pt 11)():1909-20. PubMed ID: 6094709
[TBL] [Abstract][Full Text] [Related]
34. Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge.
Grosfeld H; Velan B; Leitner M; Cohen S; Lustig S; Lachmi BE; Shafferman A
J Virol; 1989 Aug; 63(8):3416-22. PubMed ID: 2473217
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.
Määttä AM; Liimatainen T; Wahlfors T; Wirth T; Vähä-Koskela M; Jansson L; Valonen P; Häkkinen K; Rautsi O; Pellinen R; Mäkinen K; Hakumäki J; Hinkkanen A; Wahlfors J
Int J Cancer; 2007 Aug; 121(4):863-70. PubMed ID: 17443493
[TBL] [Abstract][Full Text] [Related]
36. Immunocytochemical evidence for Semliki Forest virus antigen persistence in mouse brain.
Khalili-Shirazi A; Gregson N; Webb HE
J Neurol Sci; 1988 May; 85(1):17-26. PubMed ID: 3385428
[TBL] [Abstract][Full Text] [Related]
37. Blood-brain barrier breakdown and increased intercellular adhesion molecule (ICAM-1/CD54) expression after Semliki Forest (A7) virus infection facilitates the development of experimental allergic encephalomyelitis.
Erälinna JP; Soilu-Hänninen M; Röyttä M; Hukkanen V; Salmi AA; Salonen R
J Neuroimmunol; 1996 May; 66(1-2):103-14. PubMed ID: 8964903
[TBL] [Abstract][Full Text] [Related]
38. Production of defective interfering virus in the brains of mice by an avirulent, in contrast with a virulent, strain of Semliki forest virus.
Woodward CG; Smith H
Br J Exp Pathol; 1975 Aug; 56(4):363-72. PubMed ID: 1174462
[TBL] [Abstract][Full Text] [Related]
39. Molecular determinants of alphavirus neurovirulence: nucleotide and deduced protein sequence changes during attenuation of Venezuelan equine encephalitis virus.
Johnson BJ; Kinney RM; Kost CL; Trent DW
J Gen Virol; 1986 Sep; 67 ( Pt 9)():1951-60. PubMed ID: 3755750
[TBL] [Abstract][Full Text] [Related]
40. Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine.
Snijders A; Benaissa-Trouw BJ; Oosterlaken TA; Puijk WC; Posthumus WP; Meloen RH; Boere WA; Oosting JD; Kraaijeveld CA; Snippe H
J Gen Virol; 1991 Mar; 72 ( Pt 3)():557-65. PubMed ID: 1706409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
